Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J&J Eyeing Actelion in Possible Takeover Bid

By Mike Botta | November 25, 2016

Johnson & Johnson has approached Swiss drugmaker Actelion Ltd. in a possible takeover bid, according to a report by Bloomberg that cited “people familiar with the matter.”

Actelion is a $17 billion biotech company focused largely on pulmonary arterial hypertension (PAH) medication with a portfolio of oral, inhaled and intravenous treatments.

The company targets a range of disorders around the globe, including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides in patients with cutaneous T-cell lymphoma.

While neither company involved commented on the possible takeover report, deliberations were said to be in the early stages with Actelion working with an advisor “to explore options.”

Johnson & Johnson executives previously have expressed interest in expanding the company’s portfolio in the pharmaceutical products, medical device and the consumer markets.

Actelion had been the subject of frequent acquisition rumors in the past. The company was said to be looking to reduce its reliance on the PAH drug Tracleer, which faces competition from less expensive generics early next year.

But, analysts expect revenue from the company’s PAH drug Opsumit to surpass $1 billion in 2017, while sales of its Uptravi are estimated to exceed the $1 billion mark in 2019.

Shares of Actelion rose sharply in Zurich early today following news of the possible takeover bid. By late morning, the shares were up nearly 11 percent to just under Swiss franc 175 ($173).

Johnson & Johnson on Wednesday had closed at $113.07, up 33 cents. The company is valued at more than $300 billion.

(Source: Bloomberg)


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE